Medical Faculty, University of Zurich, Zurich, Switzerland.
Department of Ophthalmology, University Hospital Zurich, Frauenklinikstrasse 24, 8091, Zurich, Switzerland.
Int Ophthalmol. 2022 May;42(5):1507-1514. doi: 10.1007/s10792-021-02140-1. Epub 2022 Feb 4.
Cataract surgery combined with excimer laser trabeculotomy (phaco-ELT) leads to a significant reduction in intraocular pressure by enhancing trabecular outflow. The aim of this study is to compare two laser systems for ELT (AIDA vs. ExTra).
In this retrospective chart review, inclusion criteria were a diagnosis of glaucoma and phaco-ELT between 07/17/2010 and 07/17/2018. Data were collected preoperatively and postoperatively up to 1 year. Success was defined as IOP reduction of ≥ 20% compared to baseline plus an IOP of < 21 mmHg with no hypotony, no loss of light perception vision, and no subsequent glaucoma surgery.
Three hundred and fourteen eyes (mean age 75.9 ± 8.6 years) were included. Baseline intraocular pressure (IOP) for the ExTra group (94 eyes) was 20.3 ± 5.9 mmHg on 2.0 ± 1.3 anti-glaucoma drugs (AGD) and a best-corrected visual acuity (BCVA, logMar) of 0.5 ± 0.4. For The AIDA group (220 eyes), baseline IOP was 18.7 ± 6.3 mmHg on 2.0 ± 1.3 AGD and a BCVA of 0.3 ± 0.3. In the ExTra group, IOP was reduced to 12.8 ± 2.5 mmHg (-37%) and in the AIDA group to 14.7 ± 3.9 (-21%, p = 0.14) at 1 year. AGD reduction in the ExTra group was 1.3 ± 1.5 and 1.8 ± 1.4 in the AIDA group (p = 0.14). Success rates were 80% (ExTra) and 70% (AIDA), respectively (p = 0.552). Thirty-one eyes (10.0%) required a subsequent glaucoma surgery during the follow-up.
Both laser platforms, the ExTra and the AIDA laser, used for Phaco-ELT lead to a significant reduction in intraocular pressure and anti-glaucoma drugs with no statistically significant difference in success rates during the follow-up of 12 months.
2018-01,791.
白内障手术联合准分子激光小梁切开术(Phaco-ELT)通过增强小梁流出而显著降低眼内压。本研究旨在比较两种用于 ELT 的激光系统(AIDA 与 ExTra)。
在这项回顾性图表审查中,纳入标准为 2010 年 7 月 17 日至 2018 年 7 月 17 日期间诊断为青光眼和白内障合并准分子激光小梁切开术。数据在术前和术后 1 年收集。成功定义为与基线相比,眼压降低≥20%,同时眼压<21mmHg,无低眼压、无光感视力丧失,且无后续青光眼手术。
共纳入 314 只眼(平均年龄 75.9±8.6 岁)。ExTra 组(94 只眼)的基线眼内压(IOP)为 20.3±5.9mmHg,使用 2.0±1.3 种抗青光眼药物(AGD),最佳矫正视力(BCVA,logMar)为 0.5±0.4。AIDA 组(220 只眼)的基线 IOP 为 18.7±6.3mmHg,使用 2.0±1.3 种 AGD,BCVA 为 0.3±0.3。在 ExTra 组,IOP 在 1 年内降低至 12.8±2.5mmHg(降低 37%),在 AIDA 组降低至 14.7±3.9mmHg(降低 21%,p=0.14)。ExTra 组的 AGD 减少量为 1.3±1.5,AIDA 组为 1.8±1.4(p=0.14)。成功率分别为 80%(ExTra)和 70%(AIDA)(p=0.552)。在随访期间,31 只眼(10.0%)需要后续青光眼手术。
用于 Phaco-ELT 的两种激光平台,即 ExTra 和 AIDA 激光,均能显著降低眼内压和抗青光眼药物,在 12 个月的随访中,成功率无统计学差异。
SWISSETHICS 2018-01,791。